USPTO serial 90064573
ABDIIBRAHIM
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 8, 2022
- Examiner
- FLETCHER, TRACY L
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ABDIIBRAHIM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Abdi Ibrahim Ilaç Sanayi ve Tic A.S.
Sariyer Istanbul, TR
Other trademarks owned by Abdi Ibrahim Ilaç Sanayi ve Tic A.S.
Abdi Ibrahim Ilaç Sanayi ve Tic A.S.
Sariyer Istanbul, TR
Other trademarks owned by Abdi Ibrahim Ilaç Sanayi ve Tic A.S.
Abdi Ibrahim Ilaç Sanayi ve Tic A.S.
Sariyer Istanbul, TR
Other trademarks owned by Abdi Ibrahim Ilaç Sanayi ve Tic A.S.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jefferson F. Scher
Jefferson F. Scher CARR & FERRELL LLP120 CONSTITUTION DRIVEMENLO PARK, CA 94025UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations used for the treatment of bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders; pharmaceutical preparations for the treatment of autoimmune, immune system, inflammatory, inflammatory bowel, gastrointestinal, genitourinary, musculoskeletal, muscular, dermatological, pulmonary, respiratory, oncological, hepatological, viral, metabolic, endocrine, cardiovascular, cardiopulmonary, sexual dysfunction, ophthalmic, neurological, hormonal, and psychiatric diseases and disorders; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, stomach, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; pharmaceutical preparations to treat or prevent diabetes, coughs, colds, influenza, headaches and allergic reactions; anti-infectives; anti-inflammatories; vaccines; dietetic substances for medical purposes, namely, nutritional, vitamin and mineral supplements and preparations; antiallergic medicines, antidiarrheal medicines, medicines for intestinal disorders, motion sickness medicines, medicines for the treatment of gastrointestinal diseases; medicines for the treatment of cardiovascular and cerebrovascular diseases; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; medicinal herbal preparations; medicinal preparations for the treatment of diseases of the mouth in the form of sprays; medicinal creams for skin care; propolis for medicinal or therapeutic purposes; medicinal preparations for the treatment of infectious diseases and for use in oncology; medicinal preparations for the treatment of diseases of the mouth to be applied in the form of drops, capsules, tablets and compressed tablets; medicinal syrups for the treatment of cold, nasal and ocular allergic rhinitis, chronic idiopathic urticaria, acute and dry cough, chronic fever, achronic hemodialyses, hyperthyroid, liver and gall bladder disorders, sudden weight loss, non-adequate and non-balanced nutrition, mouth and throat disorders, malaise and fatigue, hyozincemia, respiratory infections, treatment of zinc and iron insufficiency, treatment of irritation of throat and bronchus, and treatment of bipolar manic episode; vitamin and mineral supplements; medicinal syrups containing sodium saccarine, glycerine, banana aroma, strawberry aroma, fruit aroma, orange flavour, sucralose, nicotimanid, fish oil, pelargonium sidoides, xanthan gum, bubble gum aroma, red food dye, peach aroma, yellow food dye, raspberry extract, indigo blue food dye, and caramel for the treatment of cold, nasal and ocular allergic rhinitis, chronic idiopathic urticaria, acute and dry cough, chronic fever, achronic hemodialyses, hyperthyroid, liver and gall bladder disorders, sudden weight loss, non-adequate and non-balanced nutrition, mouth and throat disorders, malaise and fatigue, hyozincemia, respiratory infections, treatment of zinc and iron insufficiency, treatment of irritation of throat and bronchus, and treatment of bipolar manic episode; anti-diabetic pharmaceuticals; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical skin lotions; pharmaceutical preparations for skin care; pharmaceutical preparations for the treatment of erectile dysfunction; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for treating hypertension; pharmaceutical antitussive-cold preparations; pharmaceutical preparations for skin wounds; pharmaceutical preparations for treating hypoglycemia; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for treating asthma; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for treating allergic rhinitis; pharmaceutical preparations for the treatment of musculo-skeletal disorders; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for treating diseases and disorders of the central nervous system; pharmaceutical preparations for treating allergic rhinitis and asthma; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for the treatment of immune system related diseases and disorders; all of the foregoing being medicines for human health | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Abdi Ibrahim Ilaç Sanayi ve Tic A.S.
- Other trademarks owned by Abdi Ibrahim Ilaç Sanayi ve Tic A.S.
- Other trademarks owned by Abdi Ibrahim Ilaç Sanayi ve Tic A.S.
- Other trademarks in Class 005
- Similar marks named ABDIIBRAHIM
- Prosecution event R.PR explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 8, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 21, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 21, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 1, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 16, 2021 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Nov 12, 2021 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Nov 9, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 9, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 9, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 9, 2021 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| May 10, 2021 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 10, 2021 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 10, 2021 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 5, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 4, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 4, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 4, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 4, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 4, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 4, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 19, 2020 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Aug 18, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 24, 2020 | NWAP | NEW APPLICATION ENTERED | — |